| Literature DB >> 33154590 |
Stuart P Weisberg1, Thomas J Connors2, Yun Zhu2,3, Matthew R Baldwin4, Wen-Hsuan Lin1, Sandeep Wontakal1, Peter A Szabo5, Steven B Wells6, Pranay Dogra5, Joshua Gray5, Emma Idzikowski2, Debora Stelitano2,3,7, Francesca T Bovier2,3,7, Julia Davis-Porada8, Rei Matsumoto5,9, Maya Meimei Li Poon5, Michael Chait1,5, Cyrille Mathieu10, Branka Horvat10, Didier Decimo10, Krystalyn E Hudson1, Flavia Dei Zotti1, Zachary C Bitan1, Francesca La Carpia1, Stephen A Ferrara11, Emily Mace2, Joshua Milner2, Anne Moscona2,3,12,13, Eldad Hod1, Matteo Porotto14,15,16, Donna L Farber17,18,19.
Abstract
Clinical manifestations of COVID-19 caused by the new coronavirus SARS-CoV-2 are associated with age1,2. Adults develop respiratory symptoms, which can progress to acute respiratory distress syndrome (ARDS) in the most severe form, while children are largely spared from respiratory illness but can develop a life-threatening multisystem inflammatory syndrome (MIS-C)3-5. Here, we show distinct antibody responses in children and adults after SARS-CoV-2 infection. Adult COVID-19 cohorts had anti-spike (S) IgG, IgM and IgA antibodies, as well as anti-nucleocapsid (N) IgG antibody, while children with and without MIS-C had reduced breadth of anti-SARS-CoV-2-specific antibodies, predominantly generating IgG antibodies specific for the S protein but not the N protein. Moreover, children with and without MIS-C had reduced neutralizing activity as compared to both adult COVID-19 cohorts, indicating a reduced protective serological response. These results suggest a distinct infection course and immune response in children independent of whether they develop MIS-C, with implications for developing age-targeted strategies for testing and protecting the population.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33154590 PMCID: PMC8136619 DOI: 10.1038/s41590-020-00826-9
Source DB: PubMed Journal: Nat Immunol ISSN: 1529-2908 Impact factor: 25.606